Welcome to our dedicated page for Avanos Medical news (Ticker: AVNS), a resource for investors and traders seeking the latest updates and insights on Avanos Medical stock.
Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company headquartered in Alpharetta, Georgia, with a portfolio focused on nutrition support and opioid-sparing pain management. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Avanos executes its strategy across its Specialty Nutrition Systems (SNS) and Pain Management & Recovery (PM&R) segments.
Recent news releases highlight financial results, segment performance and portfolio changes. Avanos regularly reports quarterly results, detailing net sales, operating income and segment trends for SNS and PM&R, along with non-GAAP measures such as adjusted operating income, adjusted net income, adjusted diluted earnings per share, adjusted EBITDA and free cash flow. These earnings updates often discuss demand in life-sustaining enteral feeding and neonate solutions, momentum in radiofrequency ablation (RFA) solutions and changes in surgical pain and recovery product volumes.
News coverage also includes strategic transactions and partnerships. Avanos has announced the divestiture of its Hyaluronic Acid product line, including TriVisc and GenVisc 850, to Channel-Markers Medical, and an agreement for WRS Group to acquire its US Game Ready orthopedic rental business while Avanos continues to manufacture and supply Game Ready systems and accessories under a long-term agreement. On the acquisition side, Avanos has reported the purchase of Nexus Medical, adding TKO anti-reflux needleless connector technology to its Specialty Nutrition Systems business.
In addition, Avanos issues updates on leadership changes, organizational restructuring and investor events, such as webcasts of earnings conference calls and presentations at healthcare conferences. Investors and observers can use this page to review how Avanos communicates its transformation progress, portfolio focus and financial performance over time.
Avanos (NYSE: AVNS) agreed to be acquired by affiliates of American Industrial Partners for an enterprise value of approximately $1.272 billion. Avanos stockholders will receive $25.00 per share in cash, a ~72.1% premium to the April 13, 2026 close and an ~82.8% premium to the 30-day VWAP.
The transaction, unanimously approved by the Avanos board, is expected to close in the second half of 2026, is not subject to a financing condition, and will result in Avanos becoming a private company.
Avanos Medical (NYSE: AVNS) will present at the 2026 Citizens Life Sciences Conference on March 11, 2026. CEO Dave Pacitti and CFO Scott Galovan will appear in a fireside chat at ~1:05 p.m. ET.
A live webcast will be available and later archived on the company's Investors webpage.
Avanos Medical (NYSE: AVNS) announced it will nominate James L. Cunniff and William P. Burke as independent directors for election at the Company’s 2026 Annual Meeting, subject to customary background checks.
Avanos entered into a cooperation agreement with Bradley L. Radoff in connection with the nominations; the agreement will be filed as an exhibit to a Current Report on Form 8-K. The Company will include its formal board recommendation in its definitive proxy materials to be filed with the SEC. The 2026 meeting date is not yet scheduled.
Avanos Medical (NYSE: AVNS) reported fourth-quarter and full-year 2025 results on Feb 24, 2026, with full-year net sales of $701.2M and adjusted diluted EPS of $0.94. The company delivered organic growth in strategic segments, recorded a $77.0M goodwill impairment, and expects $15–20M of incremental annualized savings by end of 2026.
Q4 net sales were $180.9M, adjusted EBITDA for the year was $86.8M, year-end cash totaled $89.8M, and net debt was $10.7M.
Avanos Medical (NYSE: AVNS) will webcast a conference call to discuss fourth quarter and full year 2025 financial results on Feb. 24, 2026 at 9:00 a.m. ET. A news release with results will be issued before market open that day.
The call will be hosted by CEO Dave Pacitti and SVP/CFO Scott Galovan. Investors can join by phone, register for instant dial-in, or listen to a simultaneous webcast via the Avanos investors website. A replay will be available about two hours after the call and remain accessible for one week.
Avanos (NYSE: AVNS) announced that CMS' 2026 OPPS/ASC Final Rule maintains separate NOPAIN Act Medicare payment for the Avanos ON-Q and ambIT infusion pumps and adds Game Ready GRPro 2.1 effective Jan. 1, 2026.
CMS assigned unique HCPCS codes and published payment limits of $2,008.72 for ON-Q and ambIT, and $1,997.16 for Game Ready when medically necessary and used with a covered surgical procedure.
Avanos (NYSE: AVNS) and Siemens Healthineers announced a strategic co-marketing agreement to integrate Avanos radiofrequency ablation (RFA) technologies with Siemens mobile C-arm imaging systems for outpatient and interventional pain management.
The collaboration targets ambulatory surgery centers, hospitals, and interventional pain practices in the U.S., focusing on joint education, sales training, and marketing to promote a combined workflow that aims to improve procedural accuracy, efficiency, and consistency in patient care.
Avanos Medical (NYSE: AVNS) announced that CEO Dave Pacitti will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13, 2026 at approximately 2:15 p.m. PST. A live webcast will be available on the company Investors website and the presentation will be archived there for later viewing.
Avanos Medical (NYSE: AVNS) reported Q3 2025 results on Nov 5, 2025: total net sales of $177.8 million (+4.3% YoY) and a net loss of $1.4 million (vs. income of $5.9M a year ago). Adjusted net income was $10.1 million and adjusted diluted EPS was $0.22. The company closed the acquisition of Nexus Medical and delivered double‑digit volume growth in its Specialty Nutrition Systems (SNS) segment. Management raised and narrowed full‑year 2025 guidance to $690–700 million revenue and adjusted diluted EPS of $0.85–0.95. The company recorded a $77.0 million goodwill impairment earlier in 2025 and had $70.5 million cash and $102.8 million net debt at Sept 30, 2025.
Avanos Medical (NYSE: AVNS) will webcast a conference call on Wed., Nov 5, 2025 at 9:00 AM ET to discuss third quarter 2025 financial results and business highlights. A news release with results will be issued before market open the same day. The call will be hosted by CEO Dave Pacitti and SVP & CFO Scott Galovan. Investors can register for instant phone access, dial 1-646-357-8785 or 1-800-836-8184, or join a simultaneous webcast via the Avanos Investors website. A replay will be available within two hours after the call and accessible for one week; dial-in replay numbers and passcode 21545# are provided. Avanos is a medical technology company focused on nutrition, opioid-reduction solutions, and post-surgical recovery devices.